COPD and the metabolic syndrome: An intriguing association

Internal and Emergency Medicine

Volumn 8, Issue 4, 2013, Pages 283-289

  Clini, Enrico ^a,b   Crisafulli, Ernesto ^b   Radaeli, Alessandro ^c   Malerba, Mario ^d  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Ospedale Villa Pineta   (Italy)

^c Spedali Civili ^*  (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

COPD; Inflammation; Metabolism; Obesity

Indexed keywords

ADULT; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ADULT; HUMANS; METABOLIC SYNDROME X; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 84878333940     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0700-x     Document Type: Review

References (50)

1. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007. Available from: http://www. goldcopd. org/.
2. Fabbri LM, Luppi F, Beghé B, Rabe KF (2008) Complex chronic comorbidities of COPD. Eur Respir J 31: 204-212.
3. International Diabetes Federation. Metabolic syndrome. The IDF consensus worldwide definition of the metabolic syndrome. http://www. idf. org Accessed February 2011.
4. Crisafulli E, Gorgone P, Vagaggini B et al (2010) Efficacy of standard rehabilitation in COPD outpatients with comorbidities. Eur Respir J 36: 1042-1048.
5. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K; DECODE Study Group (2004) Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 164(10): 1066-1076.
6. Marquis K, Maltais F, Duguay V et al (2005) The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 25: 226-232.
7. Watz H, Waschki B, Kirsten A et al (2009) The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 136: 1039-1046.
8. Lam KB, Jordan RE, Jiang CQ et al (2010) Airflow obstruction and metabolic syndrome: the Guangzhou Biobank Cohort Study. Eur Respir J 35: 317-323.
9. Lakka HM, Laaksonen DE, Lakka TA et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709-2716.
10. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB (2003) The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163: 427-436.
11. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367: 1747-1757.
12. Leone N, Courbon D, Thomas F et al (2009) Lung function impairment and metabolic syndrome the critical role of abdominal obesity. Am J Respir Crit Care Med 179: 509-516.
13. Chinn DJ, Cotes JE, Reed JW (1996) Longitudinal effects of change in body mass on measurements of ventilatory capacity. Thorax 51: 699-704.
14. Guerra S, Sherrill DL, Bobadilla A, Martinez FD, Barbee RA (2002) The relation of body mass index to asthma, chronic bronchitis, and emphysema. Chest 122: 1256-1263.
15. Paek YJ, Jung KS, Hwang YI, Lee KS, Lee DR, Lee JU (2010) Association between low pulmonary function and metabolic risk factors in Korean adults: the Korean National Health and Nutrition Survey. Metabolism 59(9): 1300-1306.
16. Franssen FME, O'Donnell DE, Goossens GH, Blaak EE, Schols AWJ (2008) Obesity and the lung: 5. Obesity and COPD. Thorax 63: 1110-1117.
17. Carr DB, Utzschneider KM, Hull RL et al (2004) Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53: 2087-2094.
18. Nyholm B, Nielsen MF, Kristensen K et al (2004) Evidence of increased visceral obesity and reduced physical fitness in healthy insulin-resistant first-degree relatives of type 2 diabetic patients. Eur J Endocrinol 150: 207-214.
19. Bergman RN, van Citters GW, Mittelman SD et al (2001) Central role of the adipocyte in the metabolic syndrome. J Investig Med 49: 119-126.
20. Koehler F, Doehner W, Hoernig S, Witt C, Anker SD, John M (2007) Anorexia in chronic obstructive pulmonary disease: association to cachexia and hormonal derangement. Int J Cardiol 119: 83-89.
21. Vestbo J, Prescott E, Almdal T et al (2006) Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 173: 79-83.
22. Curtis JP, Selter JG, Wang Y et al. (2005) The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 165: 55-61. 47.
23. Ulubay G, Ulasli SS, Sahin T, Erayman Z, Gùrsoy A (2010) Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. Endocrine 38: 76-82.
24. Poulain M, Doucet M, Major GC et al (2006) The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies. Can Med Ass J 174: 1293-1299.
25. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE (1999) Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 84: 137-144.
26. Mannino DM, Thorn D, Swensen A et al (2008) Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 32: 962-969.
27. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R (2005) Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171: 972-977.
28. Watz H, Waschki B, Boehme C et al (2008) Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med 177: 743-751.
29. Calverley PM, Anderson JA, Celli B et al (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775-789.
30. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA (2008) The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177: 19-26.
31. Suissa S, Kezouh A, Ernst P (2010) Inhaled corticosteroids and the risk of diabetes onset and progression. Am J Med 123(11): 1001-1006.
32. Fabbri LM, Rabe KF (2007) From COPD to chronic systemic inflammatory syndrome? Lancet 370: 797-799.
33. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF (2007) Systemic effects of smoking. Chest 131: 1557-1566.
34. Agusti A, Thomas A (2006) Neff lecture: chronic obstructive pulmonary disease-a systemic disease. Proc Am Thorac Soc 3: 478-481.
35. Barnes PJ, Celli B (2009) Systemic manifestations and comorbidities of COPD. Eur Respir J 33: 1165-1185.
36. Wouters EFM (2005) Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thor Soc 2: 26-33.
37. Kessler R, Faller M, Fourgaut G, Mennecier M, Weitzenblum E (1999) Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 159: 158-164.
38. Ttkacova R (2010) Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Rev Lit Future Perspect Mediat Inflamm 2010: 585989.
39. Trayhurn P, Beattie JH (2001) Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 60: 329-339.
40. Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92: 347-355.
41. Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89: 2548-2556.
42. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95: 2409-2415.
43. Mohamed-Ali V, Flower L, Sethi J et al (2001) Beta-adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metabol 86: 5864-5869.
44. Bruun JM, Pedersen SB, Kristensen K, Richelsen B (2002) Opposite regulation of interleukin-8 and tumor necrosis factor-alpha by weight loss. Obesity Res 10: 499-506.
45. Hosogai H, Fukuhara A, Oshima K et al (2007) Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56: 901-911.
46. Wenger RH (2002) Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 16: 1151-1162.
47. Bolton CE, Evans M, Ionescu AA et al (2007) Insulin resistance and inflammation: a further systemic complication of COPD. J COPD 4: 121-126.
48. Sava F, Laviolette L, Breton MJ, Bourbeau J, Maltais JF (2010) The impact of obesity on walking and cycling performance and response to pulmonary rehabilitation. BMC Pulm Med 10: 55.
49. Donini ML, Savina C, Castellaneta E, Coletti C, Paolini M, Scavone L, Civale C, Ceccarelli P, Zaninotto S, Tineri M, Grossi G, De Felice MR, Cannella C (2009) Multidisciplinary approach to obesità. Eat Weight Disor 14: 23-31.
50. Han MK, Agusti A, Calverley PM et al (2010) Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 182(5): 598-604.